With Marina N. Karpenko participation, a textbook on physiology was published:

Physiology with Fundamentals of Anatomy: A Textbook / A. I. Tyukavin, N. A. Arseniev, M. N. Karpenko, et al. — 2nd ed., revised and expanded / Ser.: Higher Education: Specialist Degree. — Moscow: SRC «Infra-M», 2023. — 813 p. — DOI: 10.12 737/1904329. — ISBN: 978−5-16−18 019−9 (print); 978−5-16−111 025−6 (online).

Data on the pathogenesis of Parkinson's disease obtained with her direct involvement were included in a collective monograph:

Karpenko, M. N. Parkinson's disease / T. M. Alekseeva et al. // Neurodegenerative Diseases (Pathogenesis, Clinical Presentation, Diagnosis, Therapy) / Ed.: T. M. Alekseeva. — Saint Petersburg: SpetsLit, 2024. — Ch. 5. — P. 94−125. — ISBN: 978−5-299−1 253−8.

Over the past five years, the research focus of the Principal Investigator has been centered on developing the concept of controlled allostasis activation to expand the organism's adaptive capabilities. Studies are conducted both in clinical settings and in experimental models. With the participation of the Principal Investigator, a series of experiments has been carried out, and publications have been issued addressing, among other topics, the potential involvement of the calpain system of intracellular proteases in the regulation of allostasis, the region‑specific distribution of various calpain isoforms in the brain, as well as the protective potential of an m‑calpain inhibitor, which, according to the data obtained, should reduce the progression rate of neurodegenerative processes in Parkinson's disease. Furthermore, the Principal Investigator has demonstrated that the course of the pathological process in Parkinson's disease can be modulated by altering the levels of neurotensin and/or autoantibodies against it (Muruzheva, Z. M., Egorov, D. S., Absalyamova, M. T., Traktirov, D. S., Karpenko, M. N., Fetissov, S. O. Neurotensin‑binding immunoglobulin G in patients with Parkinson's disease // Neuroimmunomodulation. — 2023. — Vol. 30, iss. 1. — PP. 15−27. — DOI: 10.1159/527 872. — p‑ISSN: 1021‑7401; e‑ISSN: 1423‑0216.) or by controlling free copper levels (Karpenko, M. N., Muruzheva, Z. M., Ilyechova, E. Y., Babich, P. S., Puchkova, L. V. Abnormalities in copper status associated with an elevated risk of Parkinson's phenotype development // Antioxidants (Basel). — 2023. — Vol. 12, iss. 9. — Art. 1654. — 28 pp. — DOI: 10.3390/ANTIOX12091654. — ISSN: 2076‑3921).

In another series of studies, it was shown that calpain inhibition can slow the progression of the pathological process in manganese‑induced encephalopathy (Ivleva, I. S., Ivlev, A. P., Pestereva, N. S., Tyutyunnik, T. V., Karpenko, M. N. Protective effect of calpain inhibitors against manganese‑induced toxicity in rats // Metab. brain dis. — 2022. — Vol. 37, iss. 4. — PP. 1003−1013. — DOI: 10.1007/S11011‑022‑916‑7. — p‑ISSN: 0885‑7490; e‑ISSN: 1573‑7365.; Kudrinskaya VM, Ivlev AP, Obukhova DA, Maystrenko VA, Tiutiunnik TV, Traktirov DS, Karpenko MN, Ivleva IS. Spatial memory impairment is associated with decreased dopamine‑β‑hydroxylase activity in the brains of rats exposed to manganese chloride. Toxicol Mech Methods. 2024 Nov;34(9):1035‑1044. doi: 10.1080/15 376 516.2024.2 379 012. Epub 2024 Jul 17.; Sviridova VM, Ivlev AP, Kaik EA, Karpenko MN, Ivleva IS. Manganese‑induced damage to the serotoninergic system is associated with the development of anxiety and depression. Toxicol Rep. 2025 Mar 19:14:102 001. doi: 10.1016/j.toxrep.2025.102 001. eCollection 2025 Jun.).

The Principal Investigator has also participated in a series of studies addressing the adaptogenic properties of resveratrol and its potential use in preventing the development of PTSD in individuals who have experienced a traumatic situation (Tseilikman, V. E., Tseilikman, O. B., Pashkov, A. A., Ivleva, I. S., Karpenko, M. N., Shatilov, V. A., Zhukov, M. S., Fedotova, J. O., Kondashevskaya, M. V., Downey, H. F., Manukhina, E. B. Mechanisms of susceptibility and resilience to PTSD: role of dopamine metabolism and BDNF expression in the hippocampus — DOI: 10.3390/ijms232314575; Tseilikman, V. E., Fedotova, J. O., Tseilikman, O. B., Novak, J., Karpenko, M. N., Maistrenko, V. A., Lazuko, S. S., Belyeva, L. E., Kamel, M., Buhler, A. V., Kovaleva, E. G. Resistance to resveratrol treatment in experimental PTSD is associated with abnormalities in hepatic metabolism of glucocorticoids — DOI: 10.3390/IJMS24119333; Tseilikman, V. E., Shatilov, V. A., Zhukov, M. S., Buksha, I. A., Epitashvily, A. E., Lipatov, I. A., Aristov, M. R., Koshelev, A. G., Karpenko, M. N., Traktirov, D. S., Maistrenko, V. A., Kamel, M., Buhler, A. V., Kovaleva, E. G., Kalinina, T. S., Pashkov, A. A., Kon'kov, V. V., Novak, J., Tseilikman, O. B. Limited cheese intake paradigm replaces patterns of behavioral disorders in experimental PTSD: focus on resveratrol supplementation — DOI: 10.3390/IJMS241814343).